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Type 2 diabetes mellitus (T2DM) is highly predictive of cardiovascular diseases and can have 
particularly deleterious health impacts in people with severe mental illness (SMI), i.e. 
schizophrenia, bipolar disorder or major depressive disorder. This meta-analysis aimed: a) to 
describe pooled frequencies of T2DM in people with SMI; b) to analyze the influence of 
demographic, illness and treatment variables as well as T2DM assessment methods; and c) to 
describe T2DM prevalence in studies directly comparing persons with each specific SMI 
diagnosis to general population samples. The trim and fill adjusted pooled T2DM prevalence 
among 438,245 people with SMI was 11.3% (95% CI: 10.0%-12.6%). In antipsychotic-naïve 
participants, the prevalence of T2DM was 2.9% (95% CI: 1.7%-4.8%). There were no 
significant diagnostic subgroup differences. A comparative meta-analysis established that 
multi-episode persons with SMI (N=133,470) were significantly more likely to have T2DM 
than matched controls (N=5,622,664; relative risk, RR=1.85, 95% CI: 1.45-2.37, p<0.001). 
The T2DM prevalence was consistently elevated in each of the three major diagnostic 
subgroups compared to matched controls. Higher T2DM prevalences were observed in 
women with SMI compared to men (RR=1.43, 95% CI: 1.20-1.69, p<0.001). Multi-episode 
(versus first-episode) status was the only significant predictor for T2DM in a multivariable 
meta-regression analysis (r²=0.52, p<0.001). The T2DM prevalence was higher in patients 
prescribed antipsychotics, except for aripriprazole and amisulpride. Routine screening and 
multidisciplinary management of T2DM is needed. T2DM risks of individual antipsychotic 
medications should be considered when making treatment choices.  
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People with severe mental illness (SMI) – defined as schizophrenia, bipolar disorder or 
major depressive disorder (MDD) – have a two to three times higher risk for premature death 
than the general population (1,2). This mortality gap translates to a 10-20 year shortened life 
expectancy (3,4)
 
and appears to be widening (5). The most important cause for this shortened 
life expectancy is cardiovascular disease (CVD) (6). Major risk factors include antipsychotic 
medication use and an unhealthy lifestyle (7), and these risks are compounded by obstacles in 
access to medical care (8-12).  
Type 2 diabetes mellitus (T2DM) is a major risk factor for CVD. It confers an about  
two-fold excess risk for coronary heart disease, major stroke subtypes, and deaths attributed 
to other vascular causes (13,14). Prevention and treatment of T2DM demands careful 
consideration in clinical practice, particularly in populations with an increased risk for CVD 
and associated premature mortality (15,16).  
Recent meta-analyses (17-20) demonstrated that all diagnostic SMI subgroups have a 
higher risk for developing T2DM than the general population. However, meta-analytic data 
comparing T2DM risks across different psychiatric diagnoses are currently lacking. 
Furthermore, there are no meta-analytic data that combine all major diagnostic SMI 
subgroups, and information on the prevalence of T2DM among people with SMI prescribed 
different antipsychotic medication classes is insufficient.  
Large-scale pooled analyses in the SMI population are relevant, as they enable 
investigation of risk factors across large numbers of studies and participants, distinguishing 
risk factors for T2DM associated with specific SMIs from those independent of these 
illnesses. Pooling data across major diagnostic categories allows for investigation of the effect 
of demographic variables (gender, age, illness duration, study setting, geographical region) 
and treatments (particularly mood stabilizers and antipsychotics prescribed for psychotic and 
non-psychotic conditions). If risk stratification is observed, this could potentially guide 
clinicians in monitoring and treatment.   
Given the aforementioned gaps within the literature, we conducted a large scale 
systematic review and meta-analysis of pooled T2DM prevalences in people with 
schizophrenia or related psychotic disorders, bipolar disorder or MDD. We aimed to: a) 
describe pooled T2DM frequencies in people with SMI; b) analyze the influence of 
demographic, illness and treatment variables as well as T2DM assessment methods; and c) 
describe T2DM prevalence in studies directly comparing persons with each specific SMI 
diagnosis to general population samples. 
 
Methods 
 
Inclusion and exclusion criteria 
 
This systematic review was conducted in accordance with the Meta-analysis of 
Observational Studies in Epidemiology (MOOSE) guidelines (21) and in line with the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard 
(22).  
We included observational studies (cross-sectional, retrospective and prospective studies) 
and randomized controlled trials in adults with a psychiatric diagnosis of schizophrenia or 
related psychotic disorders, bipolar disorder or MDD according to the DSM-IV-TR or the 
ICD-10, irrespective of clinical setting (inpatient, outpatient or mixed, community setting), 
that reported study-defined T2DM prevalences.  
We excluded studies restricted to patients with or without cardiovascular diseases. When 
required, we contacted the primary or corresponding authors of studies to confirm eligibility, 
and to obtain the data needed for analysis if they were not available in the published paper.   
 
Search criteria, study selection and critical appraisal 
 
Two independent reviewers (DV, BS) searched Medline, PsycARTICLES, Embase and 
CINAHL from database inception to August 1, 2015, without language restrictions. Key 
words used were “diabetes” OR “glucose” AND “severe mental illness” OR “serious mental 
illness” OR “schizophrenia” OR “psychosis” OR “bipolar disorder” OR “depression” OR 
“depressive disorder” in the title, abstract or index term fields. Manual searches were also 
conducted using the reference lists from recovered articles and recent systematic reviews.  
After the removal of duplicates, the reviewers screened the titles and abstracts of all 
potentially eligible articles. They both applied the eligibility criteria, and a list of full text 
articles was developed through consensus. Next, the two reviewers considered the full texts of 
these articles and the final list of included articles was reached through consensus. A third 
reviewer (CC) was available for mediation throughout this process. Methodological appraisal 
included evaluation of bias (confounding, overlapping data, publication bias).  
 
 
 
Statistical analyses 
 
Due to anticipated heterogeneity, a random effects meta-analysis was employed. 
Heterogeneity was measured with the Q statistic (which is always presented at the end of the 
description of the results as a second or final p-value).  
We calculated the relative risk (RR) to investigate the T2DM prevalence within and 
across SMI subgroups, the latter only in those studies directly comparing diagnostic 
subgroups. Moreover, we compared the prevalence of T2DM between people with 
schizophrenia, bipolar disorder and MDD and general population control groups that were 
matched on age and sex, using data from studies in which they were directly compared. In 
both analyses, only comparisons of specific SMI groups or a SMI group with a matched 
general population group were included that had been performed within the same study, in 
order to minimize variability of T2DM frequencies due to different sampling and assessment 
procedures.  
Furthermore, in the entire dataset, we conducted subgroup analyses to investigate 
differences between the three main diagnostic subgroups, first-episode versus multi-episode 
illness, males versus females, population based versus non-population based studies, and 
differences across medication classes (antipsychotics, antidepressants, mood stabilizers) and 
geographical regions. In order to reduce heterogeneity, we did not calculate diagnostic and 
gender differences across studies, but pooled only data of studies that compared these 
differences on a patient level. Further, we conducted meta-regression analyses to investigate 
potential moderators (age, percentage of males, illness duration, smoking prevalence, and 
T2DM assessment methods) with Comprehensive Meta Analysis (version 3).   
Publication bias was tested using the Egger’s regression method (23) and Begg-
Mazumdar test (24), with a p-value <0.05 suggesting the presence of bias. When we 
encountered publication bias, we conducted a trim and fill adjusted analysis (25) to remove 
the most extreme small studies from the positive side of the funnel plot, and recalculated the 
effect size iteratively, until the funnel plot was symmetrical around the (new) effect size. 
 
 
 
 
 
 
Results 
 
Search results and included participants 
 
After excluding duplicates and irrevelant hits, our search yielded 323 publications, of 
which 118 (including 135 T2DM prevalences) met inclusion criteria (Figure 1). A list of the 
included and excluded studies (with reasons) is available upon request from the first author.  
The final sample comprised 438,245 unique persons with SMI and 5,622,664 matched 
controls. Sample sizes ranged from 12 to 143,943 participants, with a median sample size of 
270. The mean age of participants with SMI was 44.3 years (range 23.1-77.6 years); 56.8% 
(range 0-100) were male; 69% were Caucasian (range 0-100; 37 studies). Mean illness 
duration was 16.1 years (range 0-35 years; 29 studies). Thirty-one studies (N=77,028) 
reported smoking frequencies, and 44.5% (95% CI: 29.2%-60.4%) of the included 
participants smoked.  
 
T2DM prevalence 
 
The estimated weighted mean prevalence of T2DM among 438,245 people with SMI was 
10.2% (95% CI: 9.1%-11.4%; Q=14228.7, p<0.001). The Begg-Mazumdar (Kendall's 
tau=0.15, p=0.009) and Egger test (bias=-5.39, 95% CI: -7.33 to -3.45, p<0.001) indicated 
presence of publication bias. Applying the trim and fill method, adjusting for 13 studies, the 
prevalence of T2DM was 11.3% (95% CI: 10.0%-12.6%).   
 
Subgroup analyses and predictors of T2DM  
 
Study setting and design 
 
The pooled prevalences across different treatment settings (inpatients, outpatients, 
community patients, mixed settings), study designs (cross-sectional, retrospective and 
prospective studies, and population versus non-population based), median year of data 
collection (before or after the year 2000), methods of T2DM assessment (blood testing, self-
report, charts) are summarized in Table 1. The separate meta-regressions are presented in 
Table 2.  
There were no significant differences between the various treatment settings, and data 
collection before versus after the year 2000. There was also no difference in T2DM 
prevalence between population based and non-population based studies. In contrast, a higher 
T2DM prevalence was observed in studies relying upon clinical data gleaned from file and 
chart reviews versus self-report studies. A trend for higher T2DM was found in retrospective 
studies versus cross-sectional (p=0.054) and versus prospective (p=0.053) studies. 
  
Diagnostic subgroups 
 
The pooled T2DM prevalences for the different diagnostic subgroups are presented in 
Table 1. Relative risk meta-analyses established that there was no significant difference in 
T2DM in studies directly comparing schizophrenia alone (14.1%, 95% CI: 9.8%-20.2%; Q=5, 
p=0.51; N=4,963) versus schizophrenia spectrum disorders (including schizoaffective 
disorder, schizophreniform disorder and related psychoses) (18.3%, 95% CI: 14.9%-22.2%; 
Q=2.1, p=0.34; N=694) (three studies; odds ratio, OR=0.80; 95% CI: 0.52-1.25, z=-0.97, 
p=0.33; Q=2.66, p=0.26, I²=24.9).  
The same was true for the comparison of schizophrenia (13.7%, 95% CI: 8.2%-22.1%; 
Q=131, p<0.01; N=6,005) versus bipolar disorder (13.7%, 95% CI: 9.2%-20.0%; Q=46, 
p<0.01; N=3,138) (six studies; OR=1.22, 95% CI: 0.84-1.77, z=1.08, p=0.28; Q=17.1, 
p=0.004, I²=70.8); and of schizophrenia (13.7%, 95% CI: 11.6%-16.1%; Q=0.3, p=0.58; 
N=893) versus MDD (11.1%, 95% CI: 9.2%-13.3%; N=911) (two studies; OR=1.27, 95% CI: 
0.96-1.68, z=1.66, p=0.10; Q=6.0, p=0.80, I²=0). There were insufficient studies directly 
comparing T2DM prevalence in patients with bipolar disorder versus MDD.  
Comparing T2DM in first- versus multi-episode patients within the different diagnostic 
subgroups (see Table 1) demonstrated that first-episode schizophrenia patients (4.0%, 95% 
CI: 2.5%-6.2%) had a significantly lower T2DM prevalence than multi-episode schizophrenia 
patients (13.1%, 95% CI: 11.7%-14.8%, z=-3.89, p<0.001). There were no data in first-
episode bipolar disorder or MDD patients, precluding a comparison with multi-episode 
patients. 
 
 
 
 
 
Demographic variables 
 
A relative risk meta-analysis across 29 studies (including 32 comparisons) directly 
comparing T2DM frequencies in men (N=35,400) versus women (N=33,283) with SMI found 
a higher T2DM prevalence in women (RR=1.43; 95% CI: 1.20-1.69, p<0.001). 
Pooled T2DM prevalences per geographical region are displayed in Table 1. The T2DM 
prevalence was significantly higher in North America (12.5%, 95% CI: 10.9%-14.3%; 58 
studies) than in Europe (7.7%, 95% CI: 6.3%-9.3%; 32 studies) (p<0.001). No other 
significant geographical differences were observed.   
Separate meta-regression analyses (see Table 2) revealed that higher T2DM frequencies 
were moderated by older age, longer illness duration and first-episode versus multi-episode 
status, but not by gender, ethnicity, and smoking status.  
When all significant demographic predictors were entered in a multivariable meta-
regression model, multi-episode versus first-episode status (β=1.889, 95% CI: 0.1445-3.6335, 
z=2.12, p=0.03) remained the only significant moderator of the variance of T2DM. The final 
multivariable model accounted for just over half of the between-study heterogeneity in T2DM 
frequency (r²=0.52, p<0.001).   
 
Medication use 
 
Separate meta-regression analyses (see Table 2) showed that treatment duration, 
percentage of antidepressant use and percentage of lithium use, but not percentage of mood 
stabilizers use, were significant mediators of T2DM prevalence.  
Twenty papers, including 64 analyses, reported on antipsychotics (monotherapy) and 
T2DM frequencies. The prevalence of T2DM was lowest in antipsychotic-naïve participants 
(2.9%, 95% CI: 1.7%-4.8%). Except for aripiprazole and amisulpride, all individual 
antipsychotics had significantly (p<0.05) higher T2DM risk compared to antipsychotic-naïve 
participants (see Table 1). Except for a higher risk for quetiapine versus olanzapine (p=0.04), 
we did not find any differences in risk profile between individual medications. The T2DM 
risk in people treated with clozapine tended (p=0.05) to be higher than the risk in those treated 
with olanzapine. 
 
 
Relative risk (RR) of T2DM in diagnostic subgroups compared with general population 
controls 
 
Thirty-four studies provided data on T2DM prevalences comparing multi-episode 
patients with healthy control subjects, and three studies compared first-episode schizophrenia 
patients with controls. In a pooled relative risk meta-analysis, compared with general 
population controls (N=5,622,664; 6.2%, 95% CI: 4.8%-8.0%; Q=18592, p<0.01), multi-
episode persons with SMIs (N=133,470; 12.2%, 95% CI: 9.7-15.2%; Q=6166, p<0.01) had 
significantly increased risk of T2DM (RR=1.85, 95% CI: 1.45-2.37, p<0.001; Q=1302.0, 
p<0.001; 38 studies). There was no significant difference in T2DM in first-episode patients 
(4.4%, 95% CI: 2.5%-7.6%; Q=2, p=0.4) versus controls (0.9%, 95% CI: 0.03%-2.4%; Q=3, 
p=0.3) (RR=4.64, 95% CI: 0.73-29.3, p=0.10; Q=1302.0, p=0.23; three studies). 
Compared to healthy controls, the relative risk of T2DM was 2.04 in patients with 
schizophrenia or related psychotic disorders (N=115,538; 95% CI: 1.69-2.49, p<0.001; 
Q=1302.0, p<0.001, I²=97.8; 29 studies); 1.89 in patients with bipolar disorder (N=4,688; 
95% CI: 1.29-2.77, p<0.001; Q=2.2, p=0.34, I²=7.3; six studies), and 1.43 in patients with 
MDD (N=10,895; 95% CI: 0.88-2.25, p=0.029; Q=2.15, p=0.34; three studies).  
 
 
Discussion 
 
To our knowledge, this is the first meta-analysis of T2DM including and comparing data 
from the three main SMIs, namely schizophrenia spectrum, bipolar disorder and MDD. 
Approximately one in 10 individuals with SMI (11.3%; 95% CI: 10.0%-12.6%) had T2DM, 
and the relative risk for T2DM was almost double (RR=1.85, 95% CI: 1.55-2.37) that found 
in matched general population comparison samples.  
T2DM prevalences were consistently elevated for each of the three diagnostic subgroups 
compared to the general population, and comparative meta-analyses found no significant 
differences across schizophrenia, schizophrenia spectrum disorders, bipolar disorder and 
MDD. Thus, other diagnostic-independent factors likely influence T2DM frequency, 
including hyperglycaemia following psychotropic medication use (26) and long-term 
exposure to unhealthy lifestyle behaviors (27,28), as well as potential genetic factors linking 
psychiatric and medical risk (29).  
We showed for the first time in a large scale meta-analysis that T2DM risk indeed 
increased with increasing treatment duration, supported further by a multivariate meta-
regression model in which multi-episode status remained a unique significant predictor, 
explaining half of the variance. We also observed a significantly increased prevalence of 
T2DM in North America versus Europe, in keeping with the overall population prevalences 
(30), which suggests a combined impact of genetic, lifestyle and/or environmental risk 
factors.   
Knowledge of factors associated with a high T2DM risk can help identify individuals at 
greatest need for intensive monitoring and intervention. In contrast with general population 
studies (31), we found that women with SMI had a higher risk for developing T2DM than 
men. This finding warrants further investigation, but may be related to a greater propensity to 
obesity and central obesity in women with SMI compared to men (32), since central obesity is 
a significant risk factor for hyperglycaemia. On the other hand, only a minority of analyzed 
studies did provide information about the mean age in women and men, and it is possible that 
women with schizophrenia were older, which could have confounded the results.  
Our results also show that T2DM prevalence was higher in individuals with multi-
episode schizophrenia compared with persons in their first episode. The current meta-analysis 
adds to the literature that a first-episode diagnosis is a unique predictor of lower T2DM 
prevalence independent of mean age, a finding that was also apparent in a recent analysis of 
metabolic syndrome prevalences across patients with the same three main SMIs (33). Our 
results point toward the need to adopt a prevention/early intervention approach in order to 
reduce cardiometabolic risk in people with SMI. Further research is needed to explore the 
mechanisms underlying this increased T2DM risk with the transition of the illness from an 
initial episode to a multi-episode disorder.  
Our data confirm prior data that psychotropic medication use, including that of 
antidepressants, lithium and antipsychotic medications (26), is associated with higher T2DM 
prevalence. Except for aripiprazole and amisulpride, all antipsychotics were associated with a 
significantly increased T2DM risk compared to antipsychotic-naïve patients. Variations in the 
risk for glucose abnormalities are evident in the literature, with the highest risk being 
associated with clozapine, olanzapine and quetiapine in carefully designed studies (25,34,35). 
In the current meta-analysis, quetiapine (and a trend for clozapine) was associated with an 
even higher T2DM risk than olanzapine use. However, this finding should be interpreted with 
caution, as order effects cannot be excluded, in that patients who acquired marked T2DM risk 
or developed even frank T2DM on a higher-risk agent, such as olanzapine, could have been 
switched to another antipsychotic, including quetiapine, potentially leading to risk 
misattribution.  
Finally, as expected, patient self-report yielded numerically the lowest T2DM 
prevalences; the T2DM prevalence was significantly lower compared with chart review data. 
This finding is likely due to the fact that, in chart review studies, patients were followed back 
a longer time, extending the detection period. In line with this interpretation, there was a trend 
for retrospective studies to be associated with higher T2DM prevalences than prospective 
ones.   
 
Clinical implications 
 
Our meta-analysis highlighted geographical differences in T2DM, mirroring the different 
prevalences in the general population, indicating the possible influence of lifestyle and other 
environmental factors with or without genetic risk differences. Thus, considering the observed 
increased T2DM risks, screening for and trying to minimize risk factors (including adverse 
lifestyle factors and specific antipsychotic medication choice) should be a key priority in the 
multidisciplinary treatment of people with SMI (36-39).  
Our data clearly demonstrate that people with SMI should be considered as a 
“homogeneous and important high-risk group” that needs proactive screening for T2DM. It is 
particularly important to establish baseline T2DM risk at initial presentation, so that any 
subsequent change during treatment can be monitored. The medical history and examination 
should, at a minimum, include: a) history of previous CVD, T2DM or other related diseases; 
b) family history of premature CVD, T2DM or other related diseases; c) smoking, dietary and 
physical activity habits; d) weight and height in order to calculate body mass index, and waist 
circumference; e) fasting blood glucose and/or hemoglobin A1c (HBA1c); f) blood pressure 
(measured twice and average taken); and g) past medication history (39).  
As there are differences in T2DM prevalences across assessment methods, it is 
recommended that fasting blood glucose measurements (ideally even oral glucose tolerance 
testing as the gold standard) should be obtained prior to the first prescription of antipsychotic 
medication. The frequency of glucose metabolism testing will depend on the patient’s medical 
history and the prevalence of baseline risk factors. For patients on antipsychotic medication 
with normal baseline tests, it is recommended that measurements should be repeated at 12 
weeks after initiation of treatment and at least annually thereafter, with more frequent 
assessments in high-risk patients, such as those with significant weight gain, post-partum 
diabetes or a first degree family history of diabetes (40). In patients with T2DM (and those 
with pre-diabetes), fasting blood glucose and HBA1c should be measured more frequently 
(approximately every 3-6 months). An annual examination should include measurement of 
CVD risk factors, glomerular filtration rate and albumin to creatinine ratio, an eye 
examination, ideally including fundus photography, and foot examination to diagnose early 
signs of complications (41).  
Despite the imperative to screen for T2DM, screening for T2DM and CVD risk factors is 
still suboptimal, with only slight improvement over the last decade (12). The low glucose 
screening rates (44.3%; 95% CI: 36.3%-52.4%) (12) may reflect both patient and professional 
barriers. Professional barriers to screening within mental health settings may on their turn 
reflect lack of clarity about whose clinical responsibility the screening is, lack of 
understanding about what should be measured and when, uncertainity about how to interpret 
results, and lack of access to necessary equipment (41), as well as incomplete communication 
between primary and secondary care. Without systematic screening following detailed 
recommendations and using acceptable and accurate diagnostic tests, the true prevalence of 
T2DM in patients with SMI will remain unknown and underestimated.  
Even after an established diagnosis of T2DM is made, many of those with mental ill 
health are not offered timely treatment (42). Thus, it should be clarified that routine screening 
is only the first step. Psychiatric centers should cooperate with diabetes centers to establish 
shared care pathways and ensure an integrated approach for people with mental illness and 
T2DM. Such an approach would reflect recent calls for the breaking down of the traditional 
“silo” approach to physical and mental health care, in line with the internationally endorsed 
Healthy Active Lives Declaration (www.iphys.org).  
Those with diagnosed T2DM should also be seen regularly by a multidisciplinary team, 
including physicians, diabetes nurses, physical therapists or exercise physiologists and 
dieticians, to advise not just on diabetes but also on other risk factors and medical 
comorbidities.  
When T2DM is detected, people with SMI are likely to require additional 
pharmacological management, but this is unlikely to be significantly different from the 
general population. However, clinicians should be aware that any deterioration in mental 
health may result in compromised management of T2DM, and comprehensive management 
may require an adjustment to the diabetes care plan. 
 
 
Limitations 
 
Whilst this is the most comprehensive and thorough meta-analysis of T2DM in people 
with SMI conducted to date, we acknowledge several limitations that largely reflect problems 
in the primary data.  
First, only a limited number of studies assessed T2DM using an oral glucose tolerance 
test as the gold standard. There are inherent problems with using chart reviews in relation to 
selection bias and the reliability and validity of the T2DM diagnosis. Second, because our 
study findings were mainly based on cross-sectional rather than longitudinal data, 
directionality of the association between medication use and observed T2DM risk cannot be 
deduced with certainty; that is, it is possible that those with inherently higher metabolic risk 
factors may be more likely to receive antipsychotics. Also, given that many of the studies 
reported cross-sectional data, it is possible that people with SMI deemed to be at particular 
risk for glucose abnormalities were preferentially prescribed antipsychotics perceived to be of 
lower risk, such as aripiprazole and amisulpride.  
Third, variables such as clinical subtypes of MDD and bipolar disorder were not reported 
and controlled for. Fourth, a threat to the validity of any meta-analysis is publication bias and 
heterogeneity, which we encountered in most of our analyses. Nevertheless, we adjusted for 
publication bias using the trim and fill analysis, and were able to explain over half of the 
between-study heterogeneity in our multivariable meta-regression analysis. Fifth, there were 
inadequate data on lifestyle behaviors, precluding meta-analytic assessment of these factors as 
moderating or mediating variables.  
 
Future research 
 
Since antipsychotic medications are increasingly used as first line treatments for bipolar 
disorder (43) and MDD (44), additional research on the underlying mechanisms for the 
development of hyperglycaemia after pharmacotherapy initiation is needed. Moreover, future 
studies should examine whether different clinical subtypes of depression (i.e., melancholic, 
psychotic, atypical or undifferentiated) and bipolar disorder (e.g., type 1 or 2, cyclothymic 
disorder), certain mood states (manic, depressive, mixed or euthymic), or different 
antidepressants or mood stabilizers significantly moderate T2DM risk. For example, previous 
studies (45) found that some antidepressants may, in some circumstances, reduce 
hyperglycaemia, normalize glucose homeostasis and also increase insulin sensitivity, whereas 
others, including tricyclic antidepressants, may exacerbate glycaemic dysfunction or have 
little effect on glucose homeostasis (46,47).  
Furthermore, the pathophysiology underlying the association between SMI and T2DM is 
complex and not well understood, requiring further investigation. Emerging evidence (48)
 
suggests that SMI and T2DM share some pathophysiological features, including 
hypothalamic-pituitary-adrenal and mitochondrial dysfunction, neuro-inflammation, common 
genetic links and epigenetic interactions.  
Future research should also comprehensively assess T2DM risk factors, and evaluate the 
optimal monitoring regimen and interventions. Finally, long-term follow-up is required to 
accurately document the emergence of more distal outcomes, such as ischemic heart disease, 
medical costs, and premature mortality (49). 
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Figure 1  Flow diagram for the search strategy. T2DM – Type 2 diabetes mellitus; SMI – severe mental illness, 
CVD – cardiovascular disease 
Records screened after duplicates and 
irrelevant papers were removed 
(n=323) 
Records excluded on title/abstract level 
(n=125) 
Reasons: only in diabetes patients 
(n=98), review (n=13), conference 
abstract (n=8), no full-text obtained 
(n=5), type 1 diabetes (n=1) 
Full-text articles assessed for 
eligibility (n=198) 
 
Full-texts excluded (n=90) 
Reasons: no T2DM prevalence rate 
available or obtained (n=17), no 
validated SMI diagnoses (n=16), only 
incidence rates (n=16), overlap with 
included papers (n=11), limited to 
children and adolescents (n=11), CVD 
risk factors exclusion criterion (n=7), 
CVD risk factors inclusion criterion and 
no controls (n=5), no demographic data 
obtained (n=5), not limited to SMI, 
gestational diabetes (n=2) 
Full-text articles included in the 
meta-analysis (n=118) 
 
Table 1  Subgroup analyses of moderators of type 2 diabetes mellitus (T2DM) in people with severe mental illness 
 
 Meta-analysis Heterogeneity 
  
Number of 
studies 
Pooled 
T2DM 
prevalence 
(%) 
 
95% CI 
Between- 
group 
difference 
p-value 
 
I
2
 
 
Q 
 
p-value 
Study design 
     Cross-sectional 
     Retrospective 
     Prospective  
 
70 
43 
21 
 
9.2 
12.3 
8.5 
 
7.9-10.8 
10.3-14.8 
6.2-11.5 
 
0.03 
 
97.2 
99.3 
98.7 
 
2504.2 
6436.5 
1575.0 
 
<0.001 
<0.001 
<0.001 
Population based or not 
     Population based 
     Non-population based 
 
58 
76 
 
10.0 
10.4 
 
8.5-11.6 
8.9-12.2 
 
0.70 
 
99.6 
84.6 
 
13491.3 
486.0 
 
<0.001 
<0.001 
Study setting 
     Mixed 
     Inpatient 
     Outpatient 
     Community 
 
37 
37 
36 
21 
 
8.7 
11.3 
11.5 
9.7 
 
7.1-10.5 
9.3-13.8 
9.3-14.1 
7.4-12.4 
 
0.26 
 
99.5 
93.5 
97.1 
98.4 
 
7179.8 
553.7 
1229.7 
1221.7 
 
<0.001 
<0.001 
<0.001 
<0.001 
Diabetes assessment method 
     Blood testing 
     Self-report 
     Charts and files 
 
34 
26 
53 
 
10.5 
9.3 
13.0 
 
9.8-11.2 
8.8-9.8 
11.0-15.2 
 
<0.001 
 
 
79.3 
97.4 
99.5 
 
159.3 
980.9 
11051.8 
 
<0.001 
<0.001 
<0.001 
Median year data collection 
     Before 2000 
     2000 or later 
 
18 
116 
 
9.5 
10.2 
 
6.9-12.8 
9.0-11.6 
 
 
 
97.7 
99.1 
 
728.6 
13469.1 
 
<0.001 
<0.001 
Diagnosis 
     Mixed  
 
18 
 
11.2 
 
8.5-14.6 
 
0.003 
 
99.6 
 
4011.7 
 
<0.001 
     Major depressive disorder 20 6.4 4.8-8.4  97.8 869.4 <0.001 
     Bipolar disorder 17 9.2 6.8-12.4  96.6 466.8 <0.001 
     Schizophrenia spectrum  22 11.8 9.0-15.2  99.0 5151.0 <0.001 
     Schizophrenia only 57 11.5 9.8-13.5  94.7 394.2 <0.001 
Episode        
     First-episode schizophrenia 14 4.0 2.5-6.2 <0.001 62.2 34.4 0.001 
     Multi-episode schizophrenia 67 13.1 11.7-14.8  98.9 6011.1 <0.001 
Gender        
     Male 31 7.9 5.9-10.3 <0.01 97.0 1037.5 <0.001 
     Female 31 11.3 8.6-14.7  97.5 1239.8 <0.001 
Geographical region        
     North America 58 12.5 10.9-14.3 0.007 99.0 6026.7 <0.001 
     Europe 32 7.7 6.3-9.3  98.7 2486.6 <0.001 
     Asia 28 10.6 8.5-13.1  93.1 393.9 <0.001 
     Australia 5 9.2 5.7-14.5  90.6 42.7 0.034 
     South America 5 8.6 4.8-15.1  61.7 10.4 0.006 
     Africa 2 7.0 3.1-15.0  86.6 7.5 0.65 
     Middle East 2 10.2 4.8-20.3  0 0.2 0.33 
Antipsychotic medication use        
     Antipsychotic-naïve 10 2.9 1.7-4.8 <0.001 78.0 41.0 <0.001 
     Clozapine 9 15.5 11.0-21.3  38.4 13.0 0.11 
     Olanzapine 9 10.6 7.0-15.7  2.5 8.2 0.41 
     Risperidone 9 13.2 8.8-19.4  54.2 17.4 0.026 
     Quetiapine 7 16.0 9.9-24.7  0 2.5 0.87 
     Aripiprazole 3 6.7 1.5-25.0  0 0.3 0.87 
     Amisulpride 2 3.9 0.5-25.0  0 0.6 0.44 
     Typical antipsychotics 11 10.6 7.0-15.7  57.8 23.7 0.008 
 
 
Significant between-group differences are highlighted in bold prints
Table 2  Meta-regressions of moderators of type 2 diabetes mellitus (T2DM) in people with severe mental illness 
 
         Moderator Number of 
comparisons 
       β 95% CI   p-value R² 
Design (vs. retrospective)  
     Cross-sectional 
     Prospective 
Population based (yes/no) 
 
113 
64 
134 
 
-0.35 
-0.51 
-0.002 
 
-0.72 
-1.04 
-0.34 
 
0.007 
0.008 
0.33 
 
0.054 
0.053 
0.99 
0.02 
 
 
0.00 
Setting (vs. mixed) 
     Inpatients 
     Outpatients 
     Community patients 
 
74 
73 
58 
 
0.32 
0.30 
0.19 
 
-0.12 
-0.15 
-0.32 
 
0.77 
0.76 
0.70 
 
0.15 
0.19 
0.47 
0.02 
T2DM assessment (vs. self-report)      0.09 
     Blood testing 60 -0.02 -0.53 0.49 0.92  
     Charts 87 0.63 0.18 1.07 0.006  
Publication data (before 2000 or not) 134 -0.08 -0.56 0.40 0.75 0.00 
First episode (yes/no) 81 1.31 0.80 1.81 <0.001 0.19 
Mean age (years) 118 0.05 0.03 0.07 <0.001 0.18 
Gender (% male) 123 0.25 -0.37 0.88 0.42 0.01 
Ethnicity (% Caucasian) 37 -0.65 -1.48 0.17 0.12 0.07 
Duration of illness (years) 29 0.03 0.007 0.06 0.01 0.15 
Smoking (% smokers) 31 -0.24 -1.83 1.35 0.77 0.01 
Treatment duration (years) 9 0.07 0.03 0.10 <0.001 0.72 
Antidepressants use (%) 16 2.82 1.08 4.55 0.001 0.44 
Mood stabilizers use (%) 13 -0.47 -2.09 1.14 0.57 0.06 
Lithium use (%) 
Geographical region (vs. North America) 
     Europe 
     Asia 
     Australia 
     South America 
     Africa 
11 
 
90 
86 
63 
63 
60 
3.07 
 
-0.55 
-0.23 
-0.30 
-0.48 
-0.59 
1.46 
 
-0.96 
-0.67 
-1.15 
-1.44 
-1.93 
4.68 
 
-0.13 
0.22 
0.55 
0.48 
0.75 
<0.001 
 
0.009 
0.31 
0.49 
0.32 
0.39 
0.65 
0.06 
     Middle East 60 -0.19 -1.49 1.12 0.78 
 
Significant p-values are highlighted in bold prints 
 
